Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial

IMPORTANCE: In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhund, Pardeep S., Claggett, Brian L., Talebi, Atefeh, Butt, Jawad H., Gasparyan, Samvel B., Wei, Lee-Jen, McCaw, Zachary R., Wilderäng, Ulrica, Bengtsson, Olof, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe A., Shah, Sanjiv J., Vaduganathan, Muthiah, Solomon, Scott D., McMurray, John J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134044/
https://www.ncbi.nlm.nih.gov/pubmed/37099283
http://dx.doi.org/10.1001/jamacardio.2023.0711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134044/
https://www.ncbi.nlm.nih.gov/pubmed/37099283
http://dx.doi.org/10.1001/jamacardio.2023.0711

Ejemplares similares